| ID | 1278 |
| Name of the vaccine | TETRAXIM |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 2 months to 6 years |
| Description of the vaccine | DTacP-IPV combined vaccine |
| Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
| Name of the manufacturing country | Korea, Republic of |
| Year of manufacture | 2015 |
| Clinical Phase status | Clinical - Phase 4 |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Given at 2, 4, 6 months (Primary) or 4 to 6 years (Booster) vaccination. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For diphtheria, tetanus and poliomyelitis. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT01437423 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|